Email this article Significant impact of +105 A>C promoter polymorphism in IL-18 cytokine in patients with kidney stone disease
Abstract
Background: Inflammation may be one cause of nephrolithiasis and the interleukin-18 (IL-18) encoding gene polymorphisms at +105 A>C has been implicated in several inflammation related diseases. The aim of this study was to test whether IL-18+105 A>C polymorphisms could act as genetic marker for renal stone disease. A case-control study was conducted to observe the genotype distribution of IL-18+105 A>C, to elucidate the possible role of this SNP as risk factor in renal stone development and to examine its correlation with the clinico-pathologic variables.
Methods: Using the Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) technique, we tested the genotype distribution of 160 nephrolithiasis patients in comparison with 200 disease free controls from the same geographical region.
Results: We observed significant differences of IL-18+105 A to C between the controls and patients with odds ratio 5.4 (P = 0.001). The prevalence of the variant genotypes AC + CC in the patients was higher than that in the controls (45% v/s 30%) and showed a significant association (P = 0.003). Moreover, the frequency per copy of the C allele of IL-18+105 A>C was found to be implicated more in patient group 0.27 as against only 0.16 in controls (P = 0.0003). Further, males and subjects with <45 years of age in patient group were significantly associated with variant genotype (P <0.05).
Conclusion: Thus, it is evident from our study that IL-18+105 A>C is implicated in renal stone disease, and that the rare, C related allele is connected with higher susceptibility to nephrolithiasis.
Keywords
Full Text:
PDFReferences
Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003;63:1817-23.
West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. Am J Kidney Dis. 2008;51:741-7.
Rivers K, Shetty S, Menon M. When and how to evaluate a patient with nephrolithiasis. Urol Clin North Am. 2000;27:203-13.
Polito C, La Manna A, Nappi B, Villani J, Di Toro R. Idiopathic hypercalciuria and hyperuricosuria: family prevalence of nephrolithiasis. Pediatr Nephrol. 2000;14:1102-4.
Edvardsson VO, Palsson R, Indridason OS, Thorvaldsson S, Stefansson K. Familiality of kidney stone disease in Iceland. Scand J Urol Nephrol. 2009;43:1-5.
Rendina D, Mossetti G, Viceconti R, Sorrentino M, Castaldo R, Manno G, et al. Association between vitamin D receptor gene polymorphisms and fasting idiopathic hypercalciuria in recurrent stoneforming patients. Urology. 2004;4:833-8.
Khan SR, Kok DJ. Modulators of urinary stone formation. Front Biosci. 2004;9:1450-82.
Khan SR. Role of renal epithelial cells in the initiation of calcium oxalate stones. Nephron Exp Nephrol. 2004;98:55-60.
Jonassen JA, Kohjimoto Y, Scheid CR, Schmidt M. Oxalate toxicity in renal cells. Urol Res. 2005;33:329-39.
Schepers MS, van Ballegooijen ES, Bangma CH, Verkoelen CF. Oxalate is toxic to renal tubular cells only at supraphysiologic concentrations. Kidney Int. 2005;68:1660-9.
Chen WC, Wu HC, Chen HY, Wu MC, Hsu CD, Tsai FJ. Interleukin-1beta gene and receptor antagonist gene polymorphisms in patients with calcium oxalate stones. Urol Res. 2001;29:321-4.
Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol. 2007;27:98-114.
Striz I, Krasna E, Honsova E, Lacha J, Petrickova K, Jaresova M, et al. Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft. Immunol Lett. 2005;99:30-5.
Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol. 2007;156:203-12.
Gauer S, Sichler O, Obermuller N, Holzmann Y, Kiss E, Sobkowiak E, et al. IL-18 is expressed in the intercalated cell of human kidney. Kidney Int. 2007;72:1081-7.
Kretowski A, Mironczuk K, Karpinska A, Bojaryn U, Kinalski M, Puchalski Z, et al. Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes. 2002;51:3347-9.
Lee CC, Lin WY, Wan L, Tsai Y, Lin YJ, Tsai CH, et al. Interleukin-18 gene polymorphism, but not interleukin-2 gene polymorphism, is associated with rheumatoid arthritis. Immunogenetics. 2007;59:433-9.
Chen WC, Wu HC, Chen HY, Wu MC, Hsu CD, Tsai FJ. Interleukin-1beta gene and receptor antagonist gene polymorphisms in patients with calcium oxalate stones. Urol Res. 2001;29:321-4.
Goodman HO, Holmes RP, Assimos DG. Genetic factors in calcium oxalate stone disease. J Urol. 1995;153:301-7.
Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, et al. Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer. 2008;8:32.
Dong GP, Yu ZS, Liang L, Zou CC, Fu JF, Wang CL. IL-18 gene promoter –137 C/G and –607 C/A polymorphisms in Chinese Han children with type 1 diabetes mellitus. Int J Immunogenet. 2007;34:75-9.
Kretowski A, Mironczuk K, Karpinska A, Bojaryn U, Kinalski M, Puchalski Z, et al. Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes. 2002;51:3347-9.
Lee CC, Lin WY, Wan L, Tsai Y, Lin YJ, Tsai CH, et al. Interleukin-18 gene polymorphism, but not interleukin-2 gene polymorphism, is associated with rheumatoid arthritis. Immunogenetics. 2007;59:433-9.
Lai KC, Lin WY, Man KM, Tsai CH, Chen HY, Tsai FJ, et al. Association of interleukin-18 gene polymorphisms with calcium oxalate kidney stone disease. Scand J Urol Nephrol. 2010;44:20-6.
Striz I, Krasna E, Honsova E, Lacha J, Petrickova K, Jaresova M, et al. Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft. Immunol Lett. 2005;99:30-5.
Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol. 2007;156:203-12.
Gauer S, Sichler O, Obermuller N, , Holzmann Y, Kiss E, Sobkowiak E, et al. IL-18 is expressed in the intercalated cell of human kidney. Kidney Int. 2007;72:1081-7.
Heilberg IP, Teixeira SH, Martini LA, Boim MA. Vitamin D receptor gene polymorphism and bone mineral density in hypercalciuric calcium-stone-forming patients. Nephron. 2002;90:51-7.
Nishijima S, Sugaya K, Naito A, Morozumi M, Hatano T, Ogawa Y. Association of vitamin D receptor gene polymorphism with urolithiasis. J Urol. 2002;167:2188-91.
Mittal RD, Bid HK, Kumar A, Bhandari M. Association of urokinase gene 3́-UTR polymorphism with calcium oxalate nephrolithiasis. J Endourol. 2006;20:157-60.
